Home > About Us > History and Milestones
Our Journey to Success
As a Stand Alone Company
Developing TWi's own generic and brand product for US market
Launched 2 products in TWi’s own label in US market in March
Increased holding stake in Visum to 66%
Obtained Guanfacine ER Tablet final approval from US FDA and launched the product in US
Obtained final approval of 3 ANDAs from FDA
Established US commercial operations and UK supply chain
Acquired 53% stake in Visum Pharmaceutical Co., China
Publicly listed on Taipei Exchange, stock ticker : 4180
Acquired U-Liang Pharmaceutical, Co.
Selected as "Key Counseling Mittelstand Target" by Taiwan's Industrial Development Bureau, Ministry of Economic Affairs
Began trading on the Emergin Market Board. Stock ticker: 4180
Received approval for stock public issuance
Completed share transfer with TWi Holding to allow the TWi Holdings' shareholders to directly own of TWi Pharmaceuticals' share
Chungli Plant completes PIC/C audit by FDA
Chungli Plant Passed Teva Global Quality System Audit
Completed acquisition of TWi Biotechnology, Inc. as 100% fully-owned subsidiary
Spun out the new drug development division as TWi Biotechnology, Inc. for the development of new drug
Complete corporate restructuring in which TWi Holdings had been separated from Anchen Inc. and become the parent company of TWi Pharmaceuticals, Inc.
As Anchen Inc. Subsidiary
Laying foundation for development of High Barrier Generics
Chungli plant OEM anti-epileptic drugs for Anchen and began exporting to USA
Chungli plant passed US FDA Pre-Approval Inspection
Completed acquisition of Empax Pharma and changed company name to TWi Pharmaceuticals, Inc.
Acquired Parke-Davis' production facility in Chungli
Anchen Inc. established Taiwan subsidiary, TWi Pharmaceuticals, Ltd.